Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Transcode Therapeutics (RNAZ)
Squarespace, Inc. (SQSP)
Procore Technologies, Inc. (PCOR)
Oatly Group Ab (OTLY)
Ziprecruiter, Inc. (ZIP)
Priced IPO
Save Foods (SVFD)
Vera Therapeutics, Inc. (VERA)
Digital Brands Group, Inc. (DBGI)
Ipower Inc. (IPW)
Global-e Online Ltd. (GLBE)
Similarweb Ltd. (SMWB)
Flora Growth (FLGC)
Anebulo Pharmaceuticals (ANEB)
Bowman Consulting Group Ltd. (BWMN)
Onion Global Limited (OG)
Waterdrop Inc. (WDH)
Talaris Therapeutics, Inc. (TALS)
Valneva Se (VALN)
Five Star Bancorp (FSBC)
The Honest Company Inc. (HNST)
Alfi, Inc. (ALF)
Red Cat Holdings (RCAT)
Werewolf Therapeutics Inc. (HOWL)
Vaccitech Plc. (VACC)
Endeavor Group Holdings (EDR)
More companies

Rain Therapeutics Inc. (RAIN)

Sector - Healthcare

Price chart

-9.94%
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which they are able to genetically select patients they believe will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Their lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which is oncogenic in numerous cancers. They in-licensed RAIN-32 in September 2020 based on the results of a Phase 1 clinical trial, which demonstrated meaningful antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors. Based on these data, they anticipate commencing a pivotal Phase 3 trial in LPS in the second half of 2021, a Phase 2 tumor-agnostic basket trial in certain solid tumors in the second half of 2021 and a Phase 2 trial in intimal sarcoma by early 2022. In addition to RAIN-32, they are also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Industry
Pharmaceutical Preparations
CEO CFO
Avanish Vellanki Nelson Cabatuan
Employees Founded
17 2017

Contacts

Address: 8000 Jarvis Avenue, Suite 204 Newark, Ca 94560

Telephone: (510) 953-5559

Web page: http://www.rainthera.com

IPO information

First Trade Date 4/23/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.35
Shares Revised (MM) 7.35
Expected offer amount (MM) $124.95
Realized offer amount(MM) $124.95

Financial Data (last reporting year)

Market Cap (MM) $441.49
Revenues (MM) $0
Net Income (Loss) (MM) $-21.1

Voting

What do you think will happen with the RAIN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Goldman Sachs

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Goldman Sachs/ Citigroup/ Piper Sandler/ Guggenheim Securities
CO-Managers
-

Sector: Healthcare

Tweets about $RAIN

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats